Evidence map›Paper›PMID 42167941›Full record

Trial reportBMJ open2026

Toolkit to prompt and support stopping antidepressants in general practice: an interview study exploring patient participants' experiences in the RELEASE trial.

Polyana Moura Ferreira, Suzanne McDonald, Katharine A Wallis, Maria Donald

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Polyana Moura FerreiraThe University of Queensland, Brisbane, Queensland, Australia.ORCID http://orcid.org/0009-0007-9615-5283
Suzanne McDonaldThe University of Queensland, Brisbane, Queensland, Australia.
Katharine A WallisThe University of Queensland, Brisbane, Queensland, Australia.
Maria DonaldThe University of Queensland, Brisbane, Queensland, Australia m.donald@uq.edu.au.ORCID http://orcid.org/0000-0002-4962-7627

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore patient experiences with the RELEASE (Redressing long-term antidepressant use) toolkit resources, including antidepressant hyperbolic tapering plans designed to minimise withdrawal symptoms as part of the RELEASE trial's implementation evaluation to understand what aspects of the toolkit work well and identify areas where refinement could enhance future implementation. The RELEASE intervention, a multistrategy intervention codesigned with general practitioners (GPs) and patients to prompt and support stopping long-term (>12 months) antidepressants, is being evaluated in an effectiveness-implementation hybrid type-1 cluster randomised controlled trial in general practice. STUDY

designOne-to-one semistructured qualitative interviews using reflexive thematic analysis to identify patterns of shared meaning.

settingGeneral practice, south-east Queensland, Australia.

participantsAdult participants (aged 18 years or older) taking an antidepressant long-term allocated to the intervention arm of the RELEASE trial.

results31 participants with an average duration of antidepressant use of 16.5 years (range 1-30 years) were interviewed. Seven themes were identified. Across seven themes, participants described how the RELEASE toolkit resources prompted reflection on their antidepressant use, supported informed conversations with GPs, and offered tapering plans that were both structured enough to instil confidence and flexible enough to help participants feel in control of their tapering journey. They also identified barriers, including beliefs that very small tapering doses were unnecessary, difficulty accessing the mini-doses required for hyperbolic tapering and the challenge of managing withdrawal symptoms. For those who successfully stopped, the transition was associated with a renewed sense of autonomy. Participants also offered practical suggestions to strengthen the toolkit and its broader implementation.

conclusionsThe RELEASE toolkit resources played a meaningful role in prompting and supporting informed shared decision-making and guiding attempts to stop antidepressants. Clearer messaging about the potential for withdrawal symptoms and access to mini-doses for tapering are needed to support patients to safely stop antidepressants. TRIAL REGISTRATION NUMBER: ACTRN12622001379707p; Pre-results.

Indexed as

Antidepressive AgentsDrug TaperingGeneral PracticeSubstance Withdrawal SyndromeAdultAgedFemaleHumansInterviews as TopicMaleMiddle AgedQualitative ResearchQueenslandTreatment InterruptionYoung AdultAntidepressive AgentsGeneral PracticeHealth ServicesQUALITATIVE RESEARCH

Identifiers

PMID42167941
PMCPMC13201990

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.